Alkermes to Report First Quarter Financial Results on May 1, 2024
Articolo Precedente
Articolo Successivo
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
![Alkermes to Report First Quarter Financial Results on May 1, 2024](https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg)
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alkermes-to-report-first-quarter-financial-results-on-may-1-2024-302119896.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN90413&Transmission_Id=202404171600PR_NEWS_EURO_ND__EN90413&DateId=20240417)